Lista de obras - Patrick Phillips - Dominio Público Uruguay

A Step toward an Optimized Rifampin Dose Completed.

artículo científico publicado en 2015

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

artículo científico publicado en 2017

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis

artículo científico publicado en 2013

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

artículo científico publicado en 2016

Adaptive clinical trials in tuberculosis: applications, challenges and solutions

artículo científico

An analysis with serious flaws

artículo científico publicado en 2013

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

artículo científico publicado en 2013

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

artículo científico publicado en 2017

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

artículo científico publicado en 2013

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells ⬇️

artículo científico publicado el 21 de agosto de 2010

Biomarkers and surrogate end points in clinical trials of tuberculosis treatment

artículo científico publicado en 2007

Biomarkers for tuberculosis disease activity, cure, and relapse

artículo científico publicado en 2010

Challenges in the clinical assessment of novel tuberculosis drugs.

artículo científico publicado en 2016

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.

artículo científico publicado en 2010

Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd

artículo científico publicado en 2015

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

artículo científico publicado en 2018

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

artículo científico publicado en 2016

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

artículo científico publicado en 2009

DOOR/RADAR: A Gateway Into the Unknown?

artículo científico publicado en 2015

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

artículo científico publicado en 2008

Determining the minimum clinically important differences for outcomes in the DOMINO trial.

artículo científico publicado en 2010

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

artículo científico publicado en 2012

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

artículo científico publicado en 2016

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.

artículo científico publicado en 2016

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

artículo científico publicado en 2016

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

artículo científico publicado en 2014

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance

artículo científico publicado en 2019

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

artículo científico publicado en 2014

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia

artículo científico publicado en 2010

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis

scientific article published on 24 September 2018

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

artículo científico publicado en 2012

Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?

artículo científico publicado en 2013

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape

artículo científico publicado en 2019

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

artículo científico publicado en 2016

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

artículo científico publicado en 2018

Methodological considerations in clinical trials for new MDR-TB treatment regimens.

artículo científico publicado en 2016

Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals

artículo científico publicado en 2016

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

artículo científico publicado en 2015

Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling

scientific article published on 01 March 2020

Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.

artículo científico

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

artículo científico publicado en 2018

Principles for designing future regimens for multidrug-resistant tuberculosis.

artículo científico publicado en 2013

Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate

scientific article published on 30 September 2019

Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trial

scientific article published on 18 December 2019

Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis

scientific article published on 01 December 2010

Randomized clinical trials to identify optimal antibiotic treatment duration

artículo científico publicado en 2013

Reducing relapse in tuberculosis treatment

artículo científico publicado en 2015

Reply to Dodd and Proschan

artículo científico publicado en 2012

Rethinking non-inferiority: a practical trial design for optimising treatment duration

scientific article published on 05 June 2018

Safe and effective treatment for patients with isoniazid drug resistance

artículo científico publicado en 2015

Setting Tuberculosis Regimen Development on a Firm Foundation

artículo científico publicado en 2017

Short intensified treatment in children with drug-susceptible tuberculous meningitis

artículo científico publicado en 2014

Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.

artículo científico publicado en 2015

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

artículo científico publicado en 2017

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

artículo científico publicado en 2017

The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia ⬇️

artículo científico publicado en 2016

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

artículo científico publicado en 2018

The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs.

artículo científico publicado en 2011

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

artículo científico publicado en 2014

Timing of relapse in short-course chemotherapy trials for tuberculosis.

artículo científico publicado en 2010

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

article

Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.

artículo científico publicado en 2016

Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial

artículo científico publicado en 2017

When inferiority meets non-inferiority: implications for interim analyses.

artículo científico publicado en 2012

Lista de obras de Patrick Phillips

A Step toward an Optimized Rifampin Dose Completed.

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

Adaptive clinical trials in tuberculosis: applications, challenges and solutions

An analysis with serious flaws

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells ⬇️

Biomarkers and surrogate end points in clinical trials of tuberculosis treatment

Biomarkers for tuberculosis disease activity, cure, and relapse

Challenges in the clinical assessment of novel tuberculosis drugs.

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.

Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.

Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

DOOR/RADAR: A Gateway Into the Unknown?

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

Determining the minimum clinically important differences for outcomes in the DOMINO trial.

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Methodological considerations in clinical trials for new MDR-TB treatment regimens.

Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling

Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

Principles for designing future regimens for multidrug-resistant tuberculosis.

Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate

Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trial

Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis

Randomized clinical trials to identify optimal antibiotic treatment duration

Reducing relapse in tuberculosis treatment

Reply to Dodd and Proschan

Rethinking non-inferiority: a practical trial design for optimising treatment duration

Safe and effective treatment for patients with isoniazid drug resistance

Setting Tuberculosis Regimen Development on a Firm Foundation

Short intensified treatment in children with drug-susceptible tuberculous meningitis

Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia ⬇️

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs.

The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

Timing of relapse in short-course chemotherapy trials for tuberculosis.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.

Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial

When inferiority meets non-inferiority: implications for interim analyses.